ClinicalTrials.gg
Active, not recruitingNCT04932980SPARROWUpdated Dec 8, 2025

Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD

An interventional study of Aflibercept and Brolucizumab in Wet Age-related Macular Degeneration, sponsored by Berner Augenklinik. Active, not recruiting at 1 site in Switzerland. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Berner Augenklinik · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies testing aflibercept in Macular Degeneration — 3 open to participants now, 6 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Planned enrollment
30th of 67
80 · median 54
Started
2022
with 3 others
No phase
4 of 67
none open now
Registered
49th of 67
by date

Among the 67 studies testing aflibercept in Macular Degeneration, this one is the 30th largest by planned enrollment, is one of 4 that started in 2022, is one of 4 with no phase, and was the 49th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 67 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

The currently widely established and preferred protocol for the treatment of wet age-related macular degeneration includes a loading phase of three monthly injections without interim adaptation or treatment according to disease activity, thereafter following a T\&E strategy with treatment adaptation in increments of 2-4 weeks according to disease activity. Based on pharmacological considerations regarding the vitreal half-life of the drugs, the aim of this prospective explorative study is to test whether an early extension of treatment intervals without a loading phase is an option without compromising functional outcomes. Based on a superiority of Afl compared to Ran with regard to achieving a dry retina after one year and based on studies, but in the absence of real-life experience with Bro, it seems of interest to test how far Afl and Bro are comparable in terms of their potential to extend the treatment intervals over 12 months, the time to dryness of the retina, and number of injections. Also, it is of high clinical relevance to demonstrate efficacy with longer initial treatment intervals compared to the current possibly over-treating loading-phase with three four-weekly injections.

03

Conditions studied

  • Wet Age-related Macular Degeneration

Keywords

  • wAMD
  • Treat & Extend
  • Aflibercept
  • Brolucizumab
  • Loading-phase
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active MNV secondary to nAMD, going along with vision loss
  • Patients aged 50 years or older of all sexes
  • Presence of IRF and/or SRF and/or subretinal hyperreflective material affecting the central subfield of the study eye on OCT
  • signed for this study prior to the screening visit
  • If possible: availability of a smartphone and willingness to perform self-testing with the Alleye app (soft criteria)

Exclusion criteria

Exclusion Criteria:

  • Any other cause of macular oedema
  • Structural damage to the macula precluding a visual potential
  • Optical media opacities not allowing an accurate performance of the protocol examinations
  • Any intraocular surgery within three months prior to inclusion and history of any vitreoretinal surgery
  • Advanced diabetic retinopathy potentially requiring any treatment within six months following inclusion or history of vitreal haemorrhage
  • Presence of vitreoretinal traction or tractive epiretinal membrane affecting the fovea
  • History of IVT with anti-VEGF or at any time in the study eye
  • Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.
  • Significantly worse functional prognosis in the other eye or only eye
  • Women of not willing to use an effective method of during treatment and until at least 3 months after the last treatment
  • Pregnant or lactating women
  • Any systemic auto-inflammatory and auto-immune disease requiring treatment
  • Treatment with high-dose corticosteroids (Prednisone equivalent >5mg/day), or immunomodulatory or anti-proliferative agents for any reason
  • Inability or to undergo the investigated intervention
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Aflibercept ® rapid treatment extension (T&E)

    Early treat and extend (T\&E) with Aflibercept ®. First IVT followed by control after 3 weeks and 2nd IVT after 6 weeks (= shortest treatment interval). Treatment will be adjusted according to morphologic response by adaptation of treatment intervals in +/- two-week increments.

    Drug: Aflibercept · Procedure: early treat and extend (T&E)

  • Active comparator
    Brolucizumab ® rapid treatment extension (T&E)

    Early treat and extend (T\&E) with Brolucizumab ®. First IVT followed by control after 3 weeks and 2nd IVT after 6 weeks (= shortest treatment interval). Treatment will be adjusted according to morphologic response by adaptation of treatment intervals in +/- two-week increments.

    Drug: Brolucizumab · Procedure: early treat and extend (T&E)

Interventions

  • administration of anti-VEGF Aflibercept (Eylea)

  • administration of anti-VEGF Brolucizumab (Beovu)

  • Procedureearly treat and extend (T&E)

    extension of treatment intervals (T\&E) from the beginning of treatment

06

What researchers measure

Primary outcomes

  1. Number of injections given until week 52

    number injections received by patient

    Time frame: 52 weeks

Secondary outcomes

  1. Injections until week 104

    number injections received by patient

    Time frame: 104 weeks

  2. Number of treatment failures

    number with treatment demand of less than 6 weeks at any time point

    Time frame: 52 weeks

  3. Number of treatment failures

    number with treatment demand of less than 6 weeks at any time point

    Time frame: 104 weeks

  4. Time until drying of retina

    mean interval until absence of intra- and subretinal fluid

    Time frame: 52 weeks

  5. Time until drying of retina

    mean interval until absence of intra- and subretinal fluid

    Time frame: 104 weeks

  6. portion of eyes without disease activity

    % patients with absence of intra- and subretinal fluid

    Time frame: 52 weeks

  7. portion of eyes without disease activity

    % patients with absence of intra- and subretinal fluid

    Time frame: 104 weeks

  8. eyes under treatment intervals of ≥12 weeks

    portion of eyes with stable disease under treatment intervals of ≥12 weeks

    Time frame: 52 weeks

  9. eyes under treatment intervals of ≥12 weeks

    portion of eyes with stable disease under treatment intervals of ≥12 weeks

    Time frame: 104 weeks

  10. Change in visual acuity

    change of VA in logRAD from baseline to week 52

    Time frame: 52 weeks

  11. Change in visual acuity

    change of VA in logRAD from baseline to week 104

    Time frame: 104 weeks

  12. Change in central subfield thickness (CST)

    change from baseline to week 52

    Time frame: 52 weeks

  13. Change in central subfield thickness (CST)

    change from baseline to week 104

    Time frame: 104 weeks

  14. Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters

    change from baseline to week 52

    Time frame: 52 weeks

  15. Portion of eyes gaining and loosing ≥5, ≥10, and ≥15 letters

    change from baseline to week 104

    Time frame: 104 weeks

  16. Maximal treatment interval extension

    mean treatment interval extension

    Time frame: 52 weeks

  17. Maximal treatment interval extension

    mean treatment interval extension

    Time frame: 104 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014 Sep;158(3):532-6. doi: 10.1016/j.ajo.2014.05.025. Epub 2014 May 28. PubMed 24879948 ↗
  • Garweg JG, Gerhardt C. Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - a meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2021 Aug;259(8):2181-2192. doi: 10.1007/s00417-020-05048-1. Epub 2021 Feb 2. PubMed 33528645 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Jun 2027, 61 months after the start.

Of 105 non-industry interventional studies with no phase under Macular Degeneration, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 61 months is above that.

Counting every sponsor, half of 133 studies reached it within 37 months; a quarter within 17 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2021
First posted
Jun 21, 2021
StartActual
May 9, 2022
Primary completionEst.
Jun 2027
CompletionEst.
Mar 2028
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04932980
Lead sponsor
Berner Augenklinik
Collaborators
medignition AG
Responsible party
Sponsor
First posted
Jun 21, 2021
Start date
May 9, 2022
Primary completion
Jun 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Dec 8, 2025

Study contacts

Justus G. Garweg, Prof. Dr. med.
principal investigator · Berner Augenklinik

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aflibercept · Brolucizumab

Start the discussion